Alivus Life Sciences Limited — Q3 FY26
Alivus Life Sciences reported its highest-ever quarterly revenue of ₹673 crore, up 4.8% YoY, driven by a strong CDMO recovery (85.3% YoY growth) and robust non-GPL business grow...
bullish
high
✓ Verified against BSE filing
Indian management teams deliver on roughly 12% of specific earnings-call promises. A low score does not indicate dishonesty — it reflects how aspirational forward guidance typically is.
Q2 FY26
Capex spend of ~₹250 crore in H2 FY26
Management guided for capex of approximately ₹250 crore in H2 FY26, with total FY26 capex expected to be lower than the board-approved ₹600 crore.
Missed
Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
heuristic_v1
Q2 FY26
CDMO turnaround in H2 FY26
Management expects a meaningful turnaround in CDMO performance in H2, driven by new project additions and ramp-up of existing projects.
Missed
Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
heuristic_v1